Latest news with #biopharmaceuticals
Yahoo
a day ago
- Business
- Yahoo
Molecular Health and Axxam enter into a strategic partnership to bolster the discovery of innovative targets in drug development
Pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm leads for biopharmaceutical companies MILAN, Italy and HEIDELBERG, Germany, June 04, 2025 (GLOBE NEWSWIRE) -- Axxam S.p.A., a premier provider of integrated early discovery services, and Molecular Health GmbH, a leader in artificial intelligence (AI)-driven development solutions, are announcing a strategic collaboration to accelerate the identification and validation of novel therapeutic targets across a broad range of therapeutic areas. The companies will create unprecedented synergies to deliver precise and clinically driven disease-to-target and target-to-lead solutions to the pharmaceutical and biotech industry, by integrating Molecular Health's digital drug development platform Dataome into DiscoveryMAXX, Axxam's integrated early drug discovery process, combining computational clinical-molecular insight with rigorous biological validation. Dataome curates, integrates and structures molecular, phenotypic and clinical data from public, private and proprietary datasets. Its causal insights support pharmaceutical companies in improving drug development, predicting drug safety, optimizing clinical trials and enabling data-driven investment decisions. As part of Dataome, Molecular Health applies advanced AI to analyze holistic complex datasets, helping their clients to identify novel, high-potential drug targets. These computational predictions can be seamlessly integrated into Axxam's discovery platform, which incorporates decades of expertise in biology, assay development, phenotypic and target-based screening, and compound profiling. Through this partnership, AI-derived targets undergo rigorous experimental validation, using a broad suite of advanced in-vitro technologies – including induced pluripotent stem cell (iPSC)-based models – to ensure biological and disease relevance and translational value. 'Identifying the right target is one of the most critical and challenging steps in drug discovery. At Axxam, we believe that biology-driven validation is key to translating digital assessments and predictions into real-world therapies,' said Ciriaco Maraschiello, CEO of Axxam. 'This strategic partnership between a biology powerhouse like Axxam and a precision medicine-focused AI company like Molecular Health is enabling a new level of accuracy and efficiency in the early drug discovery process, allowing our clients to make more informed decisions, faster, in both preclinical and clinical development.' 'Understanding molecular causalities and variants in phenotypes, diseases and endotypes is essential for pharma and biotech companies to improve efficiency and success rates in drug development', said Friedrich von Bohlen, CEO of Molecular Health. 'The integration of our data/AI-based knowledge, simulations and predictions with Axxam's preclinical biology and chemistry assays and expertise will offer improved and accelerated outcomes in early drug discovery. This will enable our joint clients to gain deeper insights, enhance decision-making, and expand their options for drug discovery and clinical development programs.' By building a bridge between AI-powered clinical-molecular predictions and biological insight, Axxam and Molecular Health are poised to deliver next-generation discovery programs to pharmaceutical innovators worldwide. About Axxam S.p.A. Axxam S.p.A. is a leading provider of integrated discovery services across the life sciences industry. Within the drug discovery disciplines, we support pharma, biotech companies, start-ups, patient foundations as well as academic groups in their journey from hit identification to lead generation, regardless of the therapeutic area and target class. Our services include assay development, high-throughput screening, using either Axxam's high quality compound collections (synthetic and natural) or those provided by clients, hit validation, hit-to-lead and compound management. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, visit About Molecular Health GmbH Molecular Health is a leader in data-driven software technologies for the pharmaceutical and biotechnology industries. For more than a decade, the company has combined human expertise, rigorous data curation, and advanced analytics – including artificial intelligence – to transform the world's biomedical knowledge into actionable insight. The company's Pharma AI solutions power indication and biomarker discovery, target identification and validation, clinical-trial design and simulation, endpoint optimization, and safety prediction. At the core of these capabilities is Dataome, Molecular Health's proprietary technology that integrates and contextualizes biomedical, molecular, phenotypic, and drug data to shed light on the etiology of health and more information, visit Axxam contactsAntonella Solia(Head, Marketing and Lead Generation) Molecular Health GmbH Dr. Marc-Alexander Rauschendorf(Head of Medical Affairs & Marketing) Media RelationsKatja Arnold, Eva Bauer, Laurie Doyle+49-89-210 2280molecularhealth@
Yahoo
3 days ago
- Business
- Yahoo
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other top-performing stocks on Monday. Apellis Pharmaceuticals surged by 13.05 percent on Monday to finish at $19.14 apiece after earning a higher price target from an investment firm. On Monday, Wells Fargo raised its price target for the company to $29 from $26 previously, while maintaining an 'equal weight' rating for the stock. Wells Fargo said that the adjustment reflected its optimism about Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) potential treatment for rare kidney diseases C3G and IC-MPGN, which could bolster opportunities for the company. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. Wells Fargo expected the treatment to secure an approval, but underscored the need for a clearer understanding of its potential downside risks before becoming more optimistic on the stock. In the first quarter of the year, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) widened its net loss by 39 percent to $92 million from $66 million in the same period last year. Revenues inched up by 3 percent to $166.8 million from $172.3 million year-on-year. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
3 days ago
- Business
- Yahoo
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharma company in advanced phases of development and registration for ZEPIZURE® in adults, is informing about the recent initiation of coverage by Maxim Group, the US brokerage firm dedicated to biopharmaceutical companies and other emerging growth and technology companies. In a first equity research report titled 'A Robust Needle-Free Auto-Injector Platform for Emergency Therapies', Maxim Group's Equity Research issued a first BUY recommendation on the CROSSJECT share. The price of the CROSSJECT share on the 29th of May 2025, the date of issue of the research report, was €1.77. « We are excited by this first endorsement by a leading broker-dealer firm in the U.S. specialized in emerging growth companies in life sciences. We look forward to fueling the North American investor community with further positive developments in relation with the registration of ZEPIZURE® with the FDA and with the rest of our pipeline », said Patrick ALEXANDRE, CEO of CROSSJECT. About CROSSJECT CROSSJECT SA (Euronext: ALCJ; is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with BARDA. The Company's versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing. The Company's other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * This project has been supported in whole or in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; BARDA, under contract number 75A50122C00031. About Maxim Group Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan. Maxim Group was formed in 2002 as an independent and 100% employee-owned firm providing customized solutions to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of FINRA, SIPC, and NASDAQ. *** For further information, please contact: Investor Relationsinvestors@ Attachment Maxim Group initiates the coverage of theError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
3 days ago
- Business
- Globe and Mail
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
Yahoo
4 days ago
- Business
- Yahoo
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. The acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal will add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.
